High-Dose vs. Low-Dose Dexamethasone in Patients With COVID-19: A Cohort Study in Rural Central America

Area of Science:

• Infectious Diseases
• Clinical Medicine
• Pharmacology

Background:

• Dexamethasone is a corticosteroid used to treat inflammatory conditions.
• Hypoxemic COVID-19 patients often require oxygen therapy and may benefit from anti-inflammatory treatments.
• The optimal dexamethasone dosage for hypoxemic COVID-19 patients remains under investigation.

Purpose of the Study:

• To compare clinical outcomes between low-dose (8 mg) and high-dose (24 mg) dexamethasone strategies.
• To evaluate the efficacy of different dexamethasone doses in hypoxemic COVID-19 patients requiring oxygen therapy.

Main Methods:

• Retrospective observational study including 81 hypoxemic COVID-19 patients requiring oxygen therapy.
• Patients were divided into two groups: low-dose dexamethasone (8 mg) and high-dose dexamethasone (24 mg).
• Outcomes assessed included mortality, nosocomial infections, need for high-flow oxygen, invasive mechanical ventilation, and vasopressors.

Main Results:

• No significant differences in mortality, nosocomial infections, or need for vasopressors were observed between the groups.
• While the high-dose group showed a trend towards higher invasive mechanical ventilation rates (15.00% vs. 2.56%), this was not statistically significant.
• Kaplan-Meier survival analysis revealed no significant difference in survival between the low-dose and high-dose dexamethasone groups (log-rank p-value = 0.315).

Conclusions:

• The study found no significant clinical benefit of using a high-dose (24 mg) dexamethasone strategy compared to a low-dose (8 mg) strategy in hypoxemic COVID-19 patients.
• Dexamethasone dosage did not significantly impact mortality, invasive mechanical ventilation, or other key clinical outcomes in this patient population.
• Further research may be needed to confirm these findings and explore other potential therapeutic strategies for hypoxemic COVID-19.